ZIM Laboratories reappoints directors, issues employee stock options

ZIM Laboratories Limited has re-appointed Niraj Dhadiwal and Prakash Sapkal as whole-time directors, effective October 1, 2025, for a two-year term, subject to shareholder approval. Dhadiwal, a pharmacy graduate with three decades at the company, has been instrumental in export development. Sapkal, also a pharmacy graduate with post-graduation in business administration and 26 years with the company, has overseen key operations and team building. Both directors are confirmed not to be debarred from holding office.

In a separate announcement, ZIM Laboratories' board of directors approved the allotment of 10,000 equity shares with a face value of INR 10 each to eligible employees under the "ZIM Laboratories Employee Stock Option Scheme (ESOS 2023)". This issuance, on September 19, 2025, increases the paid-up equity share capital from INR 48,72,58,140 to INR 48,73,58,140.

The new shares, issued at an exercise price of INR 77.40 per share with a premium of INR 67.40, will rank pari-passu with existing equity shares. The total issued shares after this allotment amount to 48,735,814. These disclosures were made in compliance with relevant SEBI regulations.